A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DMARD / disease-modifying antirheumatic drug

[Related PubMed/MEDLINE]
Total Number of Papers: 1048
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DMARD  (>> Co-occurring Abbreviation)
Long Form:   disease-modifying antirheumatic drug
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A systematic review on the effect of DMARDs on fertility in rheumatoid arthritis. RA
2020 Achievement of remission in two early rheumatoid arthritis cohorts implementing different treat-to-target strategies. RA, TTT
2020 An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. HZ, IRs, MACE, NMSC, PsA
2020 Association of acute myocardial infarction with seropositive rheumatoid arthritis in Korea: A nationwide longitudinal cohort study. AMI, CI, RA
2020 Association of Dysregulated Central Pain Processing and Response to Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis. CPM, EULAR, ORs, PPTs, QST, RA, TS
2020 Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis. AD, CMR, CVD, ECV, ERA, ETN, LV, MTX
2020 Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. NSAID
2020 Circulating Small Noncoding RNA Biomarkers of Response to Triple Disease-modifying Antirheumatic Drug Therapy in White Women With Early Rheumatoid Arthritis. RA, sncRNA, tiRNA
2020 Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease. ILD, RA
10  2020 Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naive patients with rheumatoid arthritis. ACR20, AEs, MTX, RA, RCTs, SUCRA
11  2020 Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). ACR, DAPSA, HAQ, LEF, MDA, MTX, PASDAS, PsA, PSAID, SF-12
12  2020 Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis. bDMARD, JIA, MTX
13  2020 Demographic, clinical, and scintigraphic comparison of patients affected by palmoplantar pustulosis and severe acne: a retrospective study. CI, IQR, OR, PPP, SA, SAPHO
14  2020 Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain. csDMARD, MTX, RA
15  2020 Effect of rheumatoid arthritis and age on metacarpal bone shaft geometry and density: A longitudinal pQCT study in postmenopausal women. BP, CSA, GC, HC, RA
16  2020 Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review. RA, SLR
17  2020 Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. cs, EULAR, GC, JAK, RA, SLR, TNFi, ts
18  2020 Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. DAS28-ESR, HAQ, HR, RA, SDFR
19  2020 Evaluating quality of care for rheumatoid arthritis for the population of Alberta using system-level performance measures. PM1, PMs, RA
20  2020 Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. cs, GCs, RA, ts
21  2020 First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study. RA, UA
22  2020 Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. ACR Pedi, BCRD, BSPAR-ETN, OR, TNFi
23  2020 High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: a cross-sectional study. bDMARD, PsA, SPAIG
24  2020 How does methotrexate work? MTX, RA
25  2020 Initiating disease-modifying anti-rheumatic drugs rapidly reduces purchases of analgesic drugs in juvenile idiopathic arthritis. CI, JIA, NSAIDs, RR
26  2020 Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis? RA
27  2020 Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury. AKI
28  2020 Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. CRI, LoA, SFR
29  2020 Methrotexate Treatment Inmunomodulates Abnormal Cytokine Expression by T CD4 Lymphocytes Present in DMARD-Naive Rheumatoid Arthritis Patients. MTX, RA
30  2020 Novel biomarkers of a peripheral blood interferon signature associated with drug-naive early arthritis patients distinguish persistent from self-limiting disease course. AUC, IFN, NIA, RA, ROC, SLA, UA
31  2020 Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. DCE, RA
32  2020 Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis. ACPA, PAD4, PADAct, PADs, RA, RF
33  2020 Placebo Response in Rheumatoid Arthritis Clinical Trials. ACR, csDMARD, RA, RCT
34  2020 Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis. MDA, PsA, RCT
35  2020 Quality improvement for rheumatoid arthritis care: results from a focus group. RA
36  2020 Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis Dataset. OPAL, RA, TNFi, ts
37  2020 Reasons for the High Cesarean Delivery Rate among Women with Ankylosing Spondylitis: Using the Korean National Health Insurance Database. AS, NSAID, TNFi
38  2020 Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis. ACPA, RA, RF
39  2020 Response to abatacept is associated with the inhibition of proteasome beta1i expression in T cells of patients with rheumatoid arthritis. ANOVA, CD, IFNs, RA
40  2020 Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. ICI, irAE, Rh-irAE
41  2020 Rheumatoid Arthritis Patient's Journey: Delay in Diagnosis and Treatment. RA, SD
42  2020 Rheumatoid Arthritis Patients, Both Newly Diagnosed and Methotrexate Treated, Show More DNA Methylation Differences in CD4+ Memory Than in CD4+ Naive T Cells. DMPs, MTX, RA
43  2020 Risk factors for cervical spine instability in patients with rheumatoid arthritis. AAS, ACPA, C-spine, RA
44  2020 Risk Factors for Increased Postoperative Pain and Recommended Orderset for Postoperative Analgesic Usage. IPT, NSAID
45  2020 Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. RA
46  2020 Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity. HAQ, RA, SDAI
47  2020 T-Cell Large Granular Lymphocyte Leukemia in a Patient With Rheumatoid Arthritis. FS, LGL, RA, T-LGL
48  2020 The Association between the Plasma Sugar and Lipid Profile with the Gene Expression of the Regulatory Protein of mTOR (Raptor) in Patients with Rheumatoid Arthritis. CVD, ELISA, RA, TNF-alpha
49  2020 Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7years. ACR, AESIs, bDMARD, LTE, RA, ROW, TB
50  2020 Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. PsA
51  2020 Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). LTBI, SABIO, TB, TNF
52  2020 Ultrasound Assessment of Disease Activity Prevents Disease-Modifying Antirheumatic Drug (DMARD) Escalation and May Reduce DMARD-Related Direct Costs in Rheumatoid Arthritis With Fibromyalgia: An Exploratory Study. FM, RA, US
53  2020 Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio. AUC, DAS28, HAQ, MTX, RA, ROC
54  2020 [Adherence to biological therapies in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. (Study ADhER-1)]. ---
55  2020 [COVID-19: treatment strategies of German-speaking pediatric rheumatologists : Results of an online survey]. HCQ, Ig, stageI
56  2020 [Targeted treatment in spondyloarthritis]. ---
57  2020 [Which patients with rheumatoid arthritis do not receive DMARD treatment? Analysis of data from the German Collaborative Arthritis Centers]. RA
58  2019 A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. CRP, ERA, ID, JIA, MTX
59  2019 Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. CIs, HRs
60  2019 ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. ACPA, MBDA, RA
61  2019 Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. ADA, BCVA
62  2019 Adherence to synthetic disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the OBSERVAR Study. RA
63  2019 Arthritis risk with immune checkpoint inhibitor therapy for cancer. ICI, irAE
64  2019 Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis. DAS28, EULAR, MTX, RA
65  2019 Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study. PsA
66  2019 Care quality for rheumatoid arthritis patients in Quebec. QI, RA
67  2019 Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. ---
68  2019 Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. CliDR, csDMARDs, DAS28, DAS28-ESR, RA, RAPID3, SDAI
69  2019 Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals. DS, JIA
70  2019 Clinical Improvements as Predictors of Improvements in Patient-Reported Outcomes: Post Hoc Analysis of a Randomized, Open-Label Study of Etanercept in Latin American Patients with Rheumatoid Arthritis. HAQ-DI, MTX, PRO, RA
71  2019 Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. ACPA, MBDA, RA
72  2019 Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. RA
73  2019 Diffuse Alveolar Hemorrhage in a Patient with Antisynthetase Syndrome. ---
74  2019 Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. BMI, MDHAQ, OA, RA, RAPID3
75  2019 Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status. ACPA, anti-CCP2, RA, RF
76  2019 Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care. DAS, HR, RA
77  2019 Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis. anti-CCP, BMS, RA
78  2019 Efficacy of leflunomide combined with ligustrazine in the treatment of rheumatoid arthritis: prediction with network pharmacology and validation in a clinical trial. ACR, LEF, Lig, RA
79  2019 Emerging drugs for the treatment of noninfectious uveitis. ---
80  2019 Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity. IQR, RA
81  2019 How Are Rheumatologists Managing Anticyclic Citrullinated Peptide Antibodies-positive Patients Who Do Not Have Arthritis? GP, RA
82  2019 How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. bDMARD, DAS, PS, RA
83  2019 Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. IA, ICI, irAE
84  2019 Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients. MTX, RA
85  2019 Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. RA
86  2019 Impact of Rheumatoid Arthritis and Its Management on Falls, Fracture and Bone Mineral Density in UK Biobank. eBMD, HES, RA
87  2019 Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis. csDMARD, PRNT, RA, YF
88  2019 Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. IR, MTX, NMA, OR, RA
89  2019 Leflunomide-induced liver injury in mice: Involvement of TLR4 mediated activation of PI3K/mTOR/NFkappaB pathway. ---
90  2019 Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. LTE, MTX
91  2019 Methotrexate for psoriatic arthritis. CI, HAQ, NNTB, PsARC, RCTs, RR
92  2019 MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis. ACR, AUC, DAS28, EULAR, miRNAs, MTX, RA
93  2019 Mortality, disability, and healthcare expenditure of patients with seropositive rheumatoid arthritis in Korea: A nationwide population-based study. CI, IRR, RA
94  2019 MTHFR C677T polymorphism increases MTX sensitivity via the inhibition of S-adenosylmethionine and de novo purine synthesis. AdoMet, MTHFR, MTX, RA
95  2019 Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. ICI, irAEs
96  2019 Myocardial Inflammation, Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis. CDAI, FDG, PET-CT, RA, SUV, SUV
97  2019 Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis. HAQ, OST, RA, RCT
98  2019 Pain and Catastrophizing in Patients With Rheumatoid Arthritis: An Observational Cohort Study. CDAI, PCS
99  2019 Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. bDMARD, RA, RAID, TSQM
100  2019 Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. OMERACT